Digoxin for COVID-19
Digoxin has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z ,
Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 ,
Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512 ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.